Starway Pharm

Sunway Pharmaceutical (commonly referred to as Starway Pharmaceutical) is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the R&D, manufacturing, and commercialization of innovative therapeutics and high-end generic medicines. The company leverages its proprietary drug delivery system (DDS) platforms to develop improved formulations and novel small molecules, particularly in the field of oncology. Its lead candidate, STW-001, is a selective FGFR inhibitor currently undergoing Phase 1/2 clinical evaluation for the treatment of advanced solid tumors. In addition to its internal pipeline, Sunway provides comprehensive CDMO services, including formulation development and GMP-compliant manufacturing for global partners. The company is publicly traded on the Beijing Stock Exchange and maintains a strong presence in the Chinese domestic market.